Doris Molina-Henry, PhD, University of Southern California, San Diego, CA, discusses the efforts and initiatives to increase participation of underrepresented groups in clinical trials. Understanding participant perspectives via evidence-based approaches is important to address central concerns. Furthermore, identifying and addressing logistical barriers such as accessibility to transportation, distance from site, and availability in schedule is key. Addressing these barriers head on and understanding why groups are disproportionality ineligible for studies is crucial, to enhance our understanding of disease pathology across different populations and to develop disease-modifying interventions for groups who are more susceptible to develop the disease. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
